Search peptides, terms, sources/
Hormonal signalling

Oxytocin

Natural hormone licensed in the UK for obstetric use; studied separately for social cognition, with mostly negative trial results.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the medicine.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use. A licence for one use does not cover any other use.

UK status
Licensed for a different useChecked
Best study type
Human trials4 human trials

What is Oxytocin?

Oxytocin is a natural hormone licensed in the UK for obstetric use, and studied separately for social cognition and autism. It is a prescription-only medicine for obstetric use only, and the research on its other uses includes large randomised trials that found no benefit on their main outcomes.

Its UK licence covers the induction and augmentation of labour and the management of postpartum haemorrhage. The research on social cognition and trust gave it intranasally, on an investigational and unlicensed basis, and its largest studies were largely negative.

Class
Neurohypophysial hormone, Nonapeptide hormone
Origin
Endogenous
UK status
Licensed for a different use
Best study type
Human trials
Evidence last reviewed

How does Oxytocin work?

Oxytocin binds its receptor, which raises calcium inside cells. In the uterus this makes the muscle contract, which explains its obstetric use. In the brain, its effects on social behaviour are far less certain, and it is unclear how much reaches the brain from a nasal spray.

The mechanism in more detail

Oxytocin binds the oxytocin receptor, a G-protein-coupled receptor coupled to intracellular signalling that raises calcium levels within target cells. In the myometrium (uterine smooth muscle), this signalling pathway has been shown to drive uterine contraction, alongside increased local prostaglandin production, which is the pharmacological basis for its licensed obstetric use.

Separately, oxytocin receptor activation in the brain has been studied for possible effects on social behaviour. Research literature notes that the mechanistic link between peripheral or intranasal administration and central receptor activation is less directly evidenced than the peripheral myometrial mechanism above, and central bioavailability following intranasal dosing is itself debated in the literature rather than established.

It is worth noting that oxytocin is sometimes described in lay and popular sources as a “bonding” or “love” hormone. This is an informal framing, not a formal pharmacological classification, and the trial evidence reviewed for social-cognition effects has generally not supported it: a large registered replication study found no evidence that intranasal oxytocin increases trust, and a large randomised trial in autism spectrum disorder found no improvement in its primary social-functioning outcomes versus placebo.

Mechanisms and targets

Central social-cognition signalling (investigational)Gq/phospholipase-C signallingMyometrial contraction (peripheral)Oxytocin receptor agonismOxytocin receptor (OTR/OXTR)

Classification and structure

Names
Oxytocin; Syntocinon (synthetic UK brand, obstetric use); informally described in lay/popular sources as the "love hormone" or "bonding hormone" (an informal framing, not a formal classification)
Class
Neurohypophysial hormone Nonapeptide hormone
Origin
Endogenous
Structure
9-amino-acid cyclic peptide (a disulfide bridge between two cysteine residues forms the ring); synthetic Syntocinon is structurally identical to endogenous human oxytocin, not a modified analogue.
Routes used in the research
Intravenous infusion for the licensed obstetric indication (per NHS clinical guidance). Intranasal administration in the social-cognition and autism research literature, a materially different route from the licensed clinical use.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Oxytocin has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the medicine.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
01112

2 of the findings graded Strong and Moderate showed no effect, so they are not counted in the evidence grade at the top of the page.

Water intoxication during labour Not graded

Prolonged intravenous administration of oxytocin at high doses with large fluid volumes can cause water intoxication with hyponatraemia during labour, due to oxytocin's antidiuretic properties (reported as approximately a hundred-fold weaker than vasopressin/ADH but clinically significant at the doses/volumes used in labour induction).

Study type
Human trial
Population
Pregnant/labouring women receiving IV oxytocin infusion for induction/augmentation of labour; evidence drawn from case reports/series accumulated over decades and reflected in current UK clinical guidance.
Source
1 NHS (Right Decisions Service et al.

Limitation: Drawn from clinical guidance and accumulated case reports rather than a dedicated randomised trial.

Limitations in full

Drawn from clinical guidance and accumulated case reports rather than a dedicated randomised trial. The underlying mechanism (antidiuretic cross-reactivity with vasopressin receptors) is well-established pharmacology.

BNF fluid-balance guidance Not graded

BNF-derived UK clinical guidance recommends mitigation measures for oxytocin-associated water intoxication risk: using an electrolyte-containing diluent (not glucose), increasing oxytocin concentration rather than infusion volume where possible, restricting oral fluid intake, and monitoring fluid balance/electrolytes. Guidance states oral and IV fluid intake should not usually exceed approximately 2,500 ml in 24 hours during labour, and that oxytocin should be stopped with senior obstetric review sought if serum sodium falls below 125 mmol/L.

Study type
Regulatory-clinical source
Population
UK obstetric clinical practice guidance.
Source
2 NHS Specialist Pharmacy Service

Limitation: Based on NHS-hosted secondary summaries of BNF advice, not the BNF text itself.

The 2005 trust game Limited

In a landmark 2005 behavioural-economics study, participants given intranasal oxytocin invested approximately 17% more money than placebo-group participants in a trust game, and the authors concluded oxytocin specifically increased willingness to accept social risk in interpersonal interaction rather than generally increasing risk tolerance.

Study type
Human trial
Population
Healthy adult male participants, double-blind, placebo-controlled trust-game design.
Source
3 Kosfeld et al., 2005

Limitation: Small, single-site original study; not independently replicated in its original effect size by the larger registered replication described below.

Registered replication, no effect Moderate No effect shown

A large-scale registered replication study found no evidence that intranasal oxytocin administration increases trusting behaviour in a trust game, either in its own dataset or in a pooled dataset combining multiple replication attempts.

Study type
Human trial
Population
Multi-site registered replication of the Kosfeld et al. trust-game paradigm.
Source
4 Nature Human Behaviour, 2020

Limitation: A registered replication is a strong design choice, but this is still effectively one large study (plus a pooled analysis) rather than an independent systematic review of the whole oxytocin/trust literature.

Autism social-functioning trial Strong No effect shown

In a large phase 2/3 randomised controlled trial, intranasal oxytocin administered over 24 weeks did not improve the trial's primary social-functioning outcome measures in children and adolescents with autism spectrum disorder compared with placebo.

Study type
Human trial
Population
Children and adolescents with autism spectrum disorder, multicentre, double-blind, placebo-controlled.
Source
5 Sikich et al., 2021

Limitation: A negative/null primary-outcome result; some secondary or exploratory measures and some smaller/shorter trials in the same literature have reported partial positive signals, so this finding documents the strongest single trial's primary result, not a claim that every oxytocin/autism study found nothing.

What safety findings have been reported?

4 safety findings are recorded for Oxytocin. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Intranasal adverse-event meta-analysis

In a Cochrane-methodology systematic review and meta-analysis of reported adverse events from long-term intranasal oxytocin treatment in autism spectrum disorder, the most common adverse effects reported were nasal discomfort (14.3%), irritability (9.0%), tiredness (7.2%), diarrhoea (4.5%), and skin irritation (4.5%).

Source
6 Cai et al., 2018

Acute intranasal administration review

A review of 38 controlled trials of single intranasal doses found no significant link to adverse effects at the doses used. It noted that repeated use was rarely studied. This is route-specific and is not reassurance about oxytocin as a whole.

Source
7 MacDonald et al., 2011

Route-specific safety distinction

None of the serious adverse effects reported with intravenous oxytocin administration for labour induction (for example water intoxication, anaphylaxis) have been reported in the intranasal-route literature reviewed, per the source cited. This is a route-specific safety distinction, not a general reassurance about oxytocin as a whole.

Source
7 MacDonald et al., 2011

Prolonged intravenous administration risk

Prolonged/excessive intravenous oxytocin administration during labour carries a documented, mechanism-consistent risk of water intoxication/hyponatraemia, managed clinically per the BNF-derived guidance summarised above.

Source
2 NHS Specialist Pharmacy Service

What is Oxytocin's UK regulatory status?

Marketing authorisation
Licensed for the obstetric indication only (labour induction/augmentation; management of postpartum haemorrhage), as Syntocinon and equivalent branded/generic synthetic oxytocin products. Not licensed for any social-cognition, bonding, autism, or general wellbeing use; the intranasal research literature is entirely outside the licensed indication.
Prescription status
Prescription-only medicine (POM), and in practice administered as a hospital/clinical-setting infusion under direct clinical supervision, not a self-administered outpatient prescription.
Medicine class
Licensed medicinal product (for the obstetric indication).
MHRA position
MHRA-authorised specifically for obstetric indications (induction/augmentation of labour, management of postpartum haemorrhage). No authorisation exists for intranasal use or for any social-cognition/behavioural indication.
Authorised use
Obstetric use only: induction of labour for medical reasons; stimulation of labour; adjunctive management of incomplete, inevitable or missed miscarriage in early pregnancy; use during caesarean section after delivery; and prevention and treatment of postpartum uterine atony and haemorrhage.
Research use
The intranasal social-cognition/autism research literature uses oxytocin as an investigational agent under standard clinical-trial frameworks (MHRA Clinical Trial Authorisation where UK-based).
Other restrictions
UK clinical guidance imposes specific dosing/fluid-management restrictions on the licensed obstetric use, precisely because of the water-intoxication risk profile; these are clinical-practice restrictions embedded in guidance rather than statutory restrictions in their own right.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use. A licence for one use does not cover any other use.

References

8 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. NHS (Right Decisions Service, NHS Scotland) Oxytocin (Syntocinon), Obstetrics, clinical guidance. NHS Scotland (rightdecisions.scot.nhs.uk) · Original ↗
  2. NHS Specialist Pharmacy Service BNF-derived guidance on managing risks of oxytocin infusion (water intoxication/hyponatraemia). sps.nhs.uk · Original ↗
  3. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005). Oxytocin increases trust in humans. NatureHuman clinical trial, RCT · DOI 10.1038/nature03701 · Original ↗
  4. Nature Human Behaviour (2020). A registered replication study on oxytocin and trust. Nature Human BehaviourHuman clinical trial, RCT · DOI 10.1038/s41562-020-0878-x · Original ↗
  5. Sikich L, et al. (2021). Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2103583 · Original ↗
  6. Cai Q, et al. (2018). Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry and Clinical NeurosciencesHuman clinical trial · DOI 10.1111/pcn.12627 · Original ↗
  7. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ (2011). A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology, 36(8):1114-1126DOI 10.1016/j.psyneuen.2011.02.015 · PMID 21429671 · Original ↗
  8. eMC (2026). Oxytocin concentrate for solution for infusion: Summary of Product Characteristics, eMC. electronic Medicines Compendium (eMC) · Original ↗

Questions about Oxytocin

What is Oxytocin?

Oxytocin is a natural hormone licensed in the UK for obstetric use, and studied separately for social cognition and autism. It is a prescription-only medicine for obstetric use only, and the research on its other uses includes large randomised trials that found no benefit on their main outcomes. Read what it is.

Is Oxytocin licensed in the UK?

PeptGuru records Oxytocin's UK status as: Licensed for a different use. The licensed products and their approved uses are listed in the UK status section. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Oxytocin show?

PeptGuru records 5 research findings for Oxytocin: 4 from human trials and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Oxytocin?

4 safety findings are recorded, including: intranasal adverse-event meta-analysis; acute intranasal administration review; route-specific safety distinction. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Oxytocin?

All 8 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · UK status re-checked against the official product information. All licensed obstetric uses are now listed.

How findings are graded: the grading method. All changes.

  • KisspeptinMetastin

    Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • KPVLys-Pro-Val

    Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

    Immune and longevityAnimal studiesEvidence reviewed
    PreliminaryNot licensed in the UK
  • PT-141 (Bremelanotide)Bremelanotide

    No UK marketing authorisation found; authorised in the US. Selective melanocortin-4 receptor agonist studied for low sexual desire in women.

    MelanocortinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine

Compare Oxytocin with Kisspeptin

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.